Junli Mou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Junli Mou has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Jianxiang Wang
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College Tianjin China
10 shared publications - Min Wang
State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
9 shared publications - Fan Ding
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
8 shared publications - Haiyan Xing
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
8 shared publications - Kejing Tang
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
8 shared publications - Manling Chen
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
8 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Source Data1 from Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells
All metabolite intensities(mouse model)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Source Data1 from Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells
All metabolite intensities(mouse model)
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells
Supplementary methods, tables,figures and figure legends
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells
Supplementary methods, tables,figures and figure legends
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Source Data2 from Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells
All metabolite intensities(patients)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Source Data2 from Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells
All metabolite intensities(patients)
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells
Metabolism plays a key role in the maintenance of normal hematopoietic stem cells (HSC) and in the development of leukemia. A better understanding of the metabolic characteristics and dependencies of preleukemic cells could help identify potential therapeutic targets to prevent leukemic transformation. As AML1–ETO, one of the most frequent fusion proteins in acute myeloid leukemia that is encoded by a RUNX1::RUNX1T1 fusion gene, is capable of generating preleukemic clones, in this study, we used a conditional Runx1::Runx1t1 knockin mouse model to evaluate preleukemic cell metabolism. AML1–ETO expression resulted in impaired hematopoietic reconstitution and increased self-renewal ability. Oxidative phosphorylation and glycolysis decreased significantly in these preleukemic cells accompanied by increased HSC quiescence and reduced cell cycling. Furthermore, HSCs expressing AML1–ETO exhibited an increased requirement for fatty acids through metabolic flux. Dietary lipid deprivation or loss of the fatty acid transporter FATP3 by targeted deletion using CRISPR/Cas9 partially restored differentiation. These findings reveal the unique metabolic profile of preleukemic cells and propose FATP3 as a potential target for disrupting leukemogenesis.Significance:Fatty acid metabolism is required for maintenance of preleukemic cells but dispensable for normal hematopoiesis, indicating that dietary lipid deprivation or inhibiting fatty acid uptake may serve as potential strategies to prevent leukemogenesis.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells
Metabolism plays a key role in the maintenance of normal hematopoietic stem cells (HSC) and in the development of leukemia. A better understanding of the metabolic characteristics and dependencies of preleukemic cells could help identify potential therapeutic targets to prevent leukemic transformation. As AML1–ETO, one of the most frequent fusion proteins in acute myeloid leukemia that is encoded by a RUNX1::RUNX1T1 fusion gene, is capable of generating preleukemic clones, in this study, we used a conditional Runx1::Runx1t1 knockin mouse model to evaluate preleukemic cell metabolism. AML1–ETO expression resulted in impaired hematopoietic reconstitution and increased self-renewal ability. Oxidative phosphorylation and glycolysis decreased significantly in these preleukemic cells accompanied by increased HSC quiescence and reduced cell cycling. Furthermore, HSCs expressing AML1–ETO exhibited an increased requirement for fatty acids through metabolic flux. Dietary lipid deprivation or loss of the fatty acid transporter FATP3 by targeted deletion using CRISPR/Cas9 partially restored differentiation. These findings reveal the unique metabolic profile of preleukemic cells and propose FATP3 as a potential target for disrupting leukemogenesis.Significance:Fatty acid metabolism is required for maintenance of preleukemic cells but dispensable for normal hematopoiesis, indicating that dietary lipid deprivation or inhibiting fatty acid uptake may serve as potential strategies to prevent leukemogenesis.
- Open Access
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells
Supplementary methods, tables,figures and figure legends
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells
Supplementary methods, tables,figures and figure legends
- Open Access
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Source Data2 from Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells
All metabolite intensities(patients)
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Source Data2 from Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells
All metabolite intensities(patients)
- Open Access
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Source Data1 from Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells
All metabolite intensities(mouse model)
- 16 December 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Source Data1 from Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells
All metabolite intensities(mouse model)
- 12 September 2024
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 84 (24) , 4233-4245
Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells
Metabolism plays a key role in the maintenance of normal hematopoietic stem cells (HSC) and in the development of leukemia. A better understanding of the metabolic characteristics and dependencies of preleukemic cells could help identify potential therapeutic targets to prevent leukemic transformation. As AML1–ETO, one of the most frequent fusion proteins in acute myeloid leukemia that is encoded by a RUNX1::RUNX1T1 fusion gene, is capable of generating preleukemic clones, in this study, we used a conditional Runx1::Runx1t1 knockin mouse model to evaluate preleukemic cell metabolism. AML1–ETO expression resulted in impaired hematopoietic reconstitution and increased self-renewal ability. Oxidative phosphorylation and glycolysis decreased significantly in these preleukemic cells accompanied by increased HSC quiescence and reduced cell cycling. Furthermore, HSCs expressing AML1–ETO exhibited an increased requirement for fatty acids through metabolic flux. Dietary lipid deprivation or loss of the fatty acid transporter FATP3 by targeted deletion using CRISPR/Cas9 partially restored differentiation. These findings reveal the unique metabolic profile of preleukemic cells and propose FATP3 as a potential target for disrupting leukemogenesis. Significance: Fatty acid metabolism is required for maintenance of preleukemic cells but dispensable for normal hematopoiesis, indicating that dietary lipid deprivation or inhibiting fatty acid uptake may serve as potential strategies to prevent leukemogenesis.
- 12 September 2024
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 84 (24) , 4233-4245
Targeting Fatty Acid Metabolism Abrogates the Differentiation Blockade in Preleukemic Cells
Metabolism plays a key role in the maintenance of normal hematopoietic stem cells (HSC) and in the development of leukemia. A better understanding of the metabolic characteristics and dependencies of preleukemic cells could help identify potential therapeutic targets to prevent leukemic transformation. As AML1–ETO, one of the most frequent fusion proteins in acute myeloid leukemia that is encoded by a RUNX1::RUNX1T1 fusion gene, is capable of generating preleukemic clones, in this study, we used a conditional Runx1::Runx1t1 knockin mouse model to evaluate preleukemic cell metabolism. AML1–ETO expression resulted in impaired hematopoietic reconstitution and increased self-renewal ability. Oxidative phosphorylation and glycolysis decreased significantly in these preleukemic cells accompanied by increased HSC quiescence and reduced cell cycling. Furthermore, HSCs expressing AML1–ETO exhibited an increased requirement for fatty acids through metabolic flux. Dietary lipid deprivation or loss of the fatty acid transporter FATP3 by targeted deletion using CRISPR/Cas9 partially restored differentiation. These findings reveal the unique metabolic profile of preleukemic cells and propose FATP3 as a potential target for disrupting leukemogenesis. Significance: Fatty acid metabolism is required for maintenance of preleukemic cells but dispensable for normal hematopoiesis, indicating that dietary lipid deprivation or inhibiting fatty acid uptake may serve as potential strategies to prevent leukemogenesis.
- 29 July 2023
- Published by Elsevier in Cytotherapy
- Vol. 25 (10) , 1080-1090
2B4 inhibits the apoptosis of natural killer cells through phosphorylated extracellular signal-related kinase/B-cell lymphoma 2 signal pathway
- 29 July 2023
- Published by Elsevier in Cytotherapy
- Vol. 25 (10) , 1080-1090
2B4 inhibits the apoptosis of natural killer cells through phosphorylated extracellular signal-related kinase/B-cell lymphoma 2 signal pathway
- Open Access
- 3 September 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (36)
Single-cell transcriptome of early hematopoiesis guides arterial endothelial-enhanced functional T cell generation from human PSCs
Hypoxia enhances hematopoiesis with functional T cell potential from human pluripotent stem cells via arterial priming.
- 3 September 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 7 (36)
Open AccessSingle-cell transcriptome of early hematopoiesis guides arterial endothelial-enhanced functional T cell generation from human PSCs
Hypoxia enhances hematopoiesis with functional T cell potential from human pluripotent stem cells via arterial priming.